First US city to defy FDA ends drug imports

3 September 2006

The first US city to defy the Food and Drug Administration's prohibition of cheaper drug imports has abandoned its scheme after three years.

The city of Springfield, Massachusetts, estimates that, by enrolling about 1,500 municipal employees and retirees, it will save up to $5.0 million per year, versus the $3.0 million it believes it saved under the Canadian drug reimportation program that has been copied by other local or state authorities across the USA (Marketletters passim).

Despite several warnings, the FDA never intervened to stop the Springfield program. Instead, 32 US Senators have signed up for a Bill that would legalize imports, an issue which the American Association of Retired Persons believes will be a significant mid-term election issue in November, when two-thirds of the USA's Governors, one-third of the Senate and the whole of the US House of Representatives are elected, as well as thousands of local government positions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight